1h Free Analyst Time
The Cell & Gene Therapy Manufacturing Services Market is projected to reach USD 19.75 Billion in 2026. It is expected to continue growing at a CAGR of 16.45%, reaching USD 49.42 Billion by 2032. Speak directly to the analyst to clarify any post sales queries you may have.
Cell and gene therapy manufacturing services sit at the center of the advanced therapy medicinal products ecosystem, enabling the translation of autologous and allogeneic cell therapies, viral vector-based gene therapies, gene-modified cell products, and genome-editing programs from clinical development to commercial supply. Demand for specialized contract development and manufacturing support is being shaped by the technical complexity of living medicines, strict regulatory expectations, cold-chain requirements, donor and patient variability, and the need for validated, reproducible, and scalable processes. Unlike conventional biologics, cell and gene therapies require tightly controlled workflows across cell sourcing, plasmid and viral vector production, transduction or gene editing, cell expansion, fill-finish, cryopreservation, analytical testing, release documentation, and chain-of-identity or chain-of-custody management. Regulatory agencies have continued to refine guidance for chemistry, manufacturing, and controls; comparability; potency assays; sterility assurance; and long-term follow-up, reinforcing the importance of quality-by-design and robust data integrity. Industry momentum is also supported by the growing number of approved advanced therapies across oncology, rare diseases, hematology, ophthalmology, and inherited disorders, as well as expanding clinical pipelines using CAR-T, TCR-T, NK cell therapy, hematopoietic stem cell approaches, AAV vectors, lentiviral vectors, and non-viral delivery platforms. For manufacturers and sponsors, competitiveness increasingly depends on process standardization, flexible capacity, automation, analytical depth, regulatory readiness, and the ability to reduce vein-to-vein timelines while maintaining patient safety and product consistency.
Transformative Shifts in Cell & Gene Therapy Manufacturing
The cell and gene therapy manufacturing landscape is shifting from highly manual, research-driven production toward industrialized, digitally enabled, and compliance-centered operating models. Early-stage therapies have historically relied on open processing, bespoke protocols, and small-batch production, but the movement toward late-stage trials and commercial supply is increasing the need for closed and automated systems, modular cleanrooms, single-use technologies, standardized raw material qualification, and scalable vector manufacturing. Autologous cell therapy manufacturing remains logistically demanding because every batch is linked to an individual patient, requiring precise scheduling, identity management, cryogenic logistics, and rapid release testing. In parallel, allogeneic platforms are driving investment in larger-batch production, master cell banks, donor screening, genome editing, immune evasion strategies, and batch comparability. Viral vector supply remains a critical technical bottleneck, particularly for AAV and lentiviral vectors, due to challenges in yield, full-empty capsid characterization, impurity clearance, and analytical standardization. Non-viral delivery, transposon systems, mRNA-enabled editing, and lipid nanoparticle approaches are also influencing manufacturing service models by introducing alternative process requirements. Regulatory scrutiny is encouraging earlier CMC planning, validated potency assays, contamination-control strategies, and lifecycle process validation. At the same time, decentralized and point-of-care manufacturing concepts are gaining attention for time-sensitive therapies, though they require harmonized quality systems and digital oversight. These transformations are redefining service provider selection, with sponsors prioritizing technical transfer strength, regulatory documentation quality, redundancy in critical supply chains, and proven capabilities across clinical and commercial manufacturing.Cumulative Impact of Artificial Intelligence on Manufacturing Services
Artificial intelligence is becoming a practical enabler across cell and gene therapy manufacturing services by improving process understanding, predictive control, quality assurance, and operational efficiency. In upstream and downstream manufacturing, AI-supported models can analyze high-dimensional process data from bioreactors, cell expansion platforms, transfection runs, purification systems, and environmental monitoring to identify drivers of variability and improve batch consistency. Machine learning methods are increasingly relevant for optimizing culture conditions, predicting cell growth and phenotype, improving viral vector yield, and supporting comparability assessments after process changes. In quality control, AI-enabled image analysis, flow cytometry interpretation, anomaly detection, and automated review of manufacturing records can shorten release timelines while strengthening data integrity, provided systems are validated and aligned with good manufacturing practice expectations. AI can also support predictive maintenance for critical equipment, scheduling of autologous patient-specific workflows, raw material demand planning, and cold-chain risk management. For advanced analytics, AI assists in linking critical process parameters to critical quality attributes, improving potency assay development and enabling more science-based control strategies. However, adoption must address validated model governance, explainability, cybersecurity, electronic record compliance, and bias in training datasets. The cumulative impact of artificial intelligence is therefore not a replacement for bioprocess expertise but a multiplier for quality-by-design, real-time decision-making, deviation prevention, and more resilient cell and gene therapy manufacturing operations.Key Regional Insights Across Advanced Therapy Manufacturing
Asia-Pacific is emerging as a highly active region for cell and gene therapy manufacturing services, supported by expanding clinical trial activity, government-backed regenerative medicine initiatives, hospital-linked innovation hubs, and investments in viral vector, cell processing, and cryogenic infrastructure across China, Japan, South Korea, Australia, Singapore, and India. Japan’s established regenerative medicine regulatory framework and South Korea’s biotechnology manufacturing capabilities strengthen regional adoption, while China’s clinical pipeline and India’s biomanufacturing talent base support broader capacity development. Europe maintains a sophisticated advanced therapy medicinal products environment with centralized regulatory pathways, strong academic-industry collaboration, and established expertise in GMP cell processing, gene therapy vectors, quality control testing, and hospital exemption frameworks. Germany, France, Italy, Spain, and the United Kingdom are influential in clinical translation, regulatory science, workforce development, and manufacturing standards for advanced therapies. North America remains a global center for advanced therapy development due to a dense clinical research network, mature regulatory engagement, strong academic medical centers, and established GMP infrastructure for autologous cell therapy, allogeneic platforms, plasmid DNA, viral vectors, analytical testing, and commercial release. The United States leads regional activity, while Canada contributes through stem cell research, translational medicine networks, and specialized bioprocessing expertise. Latin America is progressing through oncology-focused cell therapy research, public-private healthcare collaboration, and gradual expansion of regulatory frameworks, with Brazil and Mexico playing visible roles in clinical adoption, hospital-based therapy delivery, and regional manufacturing discussions. Africa remains at an earlier stage but is building relevance through genomic medicine initiatives, stem cell research, vaccine and biologics manufacturing experience, and efforts to strengthen regulatory harmonization and cold-chain systems, which are essential foundations for future cell and gene therapy manufacturing services. The Middle East is increasing investment in precision medicine, tertiary care, and national biotechnology strategies, especially in Gulf economies where healthcare infrastructure and medical innovation programs are supporting advanced therapy readiness, specialized treatment access, cryogenic logistics, and long-term localization of advanced therapy manufacturing capabilities.Key Group Insights for Cell & Gene Therapy Manufacturing
NATO countries, while not a healthcare trade bloc, include many nations with strong biomedical security priorities, resilient supply-chain initiatives, advanced sterile manufacturing infrastructure, and established regulatory systems; these factors are increasingly relevant as governments recognize cell and gene therapy manufacturing, viral vector supply, cryogenic logistics, and biomanufacturing redundancy as strategically important components of health security and innovation infrastructure. The G7 countries remain influential because of established regulatory authorities, leading academic medical centers, advanced biologics infrastructure, and high levels of clinical research activity, which collectively shape global standards for CMC documentation, patient safety, pharmacovigilance, manufacturing quality, and advanced therapy commercialization readiness. BRICS countries contribute diverse strengths: China and India provide large patient populations, growing biotechnology ecosystems, and manufacturing scale-up potential; Brazil supports Latin American clinical and regulatory development; Russia has scientific capacity in gene and cell technologies; and South Africa provides a strategic base for African biomedical collaboration and capacity building. The European Union plays a central role in harmonizing advanced therapy medicinal product regulation through centralized authorization mechanisms, pharmacovigilance requirements, GMP expectations, hospital exemption provisions, and cross-border clinical research, making the bloc a key environment for standardized cell and gene therapy manufacturing practices. ASEAN is gaining importance in cell and gene therapy manufacturing services as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines strengthen biomedical research, clinical trial capacity, regulatory modernization, and cold-chain readiness, with Singapore serving as a regional hub for GMP bioprocessing, talent development, and translational medicine. The GCC is advancing through national healthcare transformation programs, precision medicine investments, and specialized hospital networks, positioning the region for partnerships in advanced therapy clinical delivery, cryogenic logistics, technology transfer, and eventual localized manufacturing capabilities.Key Country Insights in Cell & Gene Therapy Manufacturing
The United States is the most active national environment for cell and gene therapy manufacturing services, supported by extensive clinical development, FDA regulatory pathways for biologics and advanced therapies, academic medical center networks, and demand for commercial-scale GMP capacity in CAR-T, gene therapy vectors, and genome-editing platforms. China is a major growth center for CAR-T, gene therapy research, and domestic manufacturing expansion, with increasing regulatory sophistication and broad clinical participation. India is advancing through cost-efficient biomanufacturing expertise, expanding clinical research, and policy attention to biotechnology and regenerative medicine. Germany is prominent in GMP manufacturing, industrial bioprocessing, hospital-based cell therapy, and engineering-led automation, while the United Kingdom remains a major hub for cell and gene therapy translation, with strong clinical trial infrastructure, specialist manufacturing centers, and regulatory experience in advanced therapy medicinal products. Japan benefits from a distinctive regenerative medicine framework, mature pharmaceutical quality systems, and early adoption of approved cell-based products. France combines advanced biomedical research, public health infrastructure, and cell therapy expertise, while Canada contributes through recognized strengths in stem cell science, cell therapy translation, biomanufacturing training, and collaborative research infrastructure. Brazil anchors Latin American activity with oncology research, regenerative medicine programs, and evolving regulatory oversight for advanced therapies. South Korea is recognized for strong biotechnology manufacturing, stem cell and immune cell therapy development, and government support for advanced biopharmaceutical innovation. Australia supports the field through clinical trials, biomedical research institutes, and regulatory alignment with advanced therapy standards. Italy and Spain contribute through hospital-linked advanced therapy programs, oncology research, GMP cell processing, and European clinical networks. Mexico is developing relevance through clinical research growth, proximity to North American supply chains, and investment in healthcare manufacturing capabilities. Russia has scientific capabilities in genetic technologies and cellular medicine, though international collaboration and supply chains can be affected by geopolitical constraints.Actionable Recommendations for Industry Leaders
Industry leaders should prioritize manufacturing strategies that reduce variability, strengthen regulatory confidence, and improve patient access without compromising product quality. Sponsors and service providers should engage CMC planning early, define critical quality attributes and critical process parameters, and build comparability strategies before major process changes or site transfers. Investment in closed, automated, and single-use manufacturing platforms can reduce contamination risk and support reproducibility, especially for autologous workflows where scheduling and chain-of-identity controls are essential. Organizations should expand analytical capabilities for potency, vector characterization, residual impurity testing, sterility, mycoplasma, replication-competent virus detection, and rapid release methods, since analytical bottlenecks often constrain clinical and commercial execution. Supply-chain resilience should be improved through qualified secondary suppliers for plasmids, cytokines, media, bags, filters, reagents, and cryogenic logistics, along with documented risk assessments for critical raw materials. Digital manufacturing execution systems, electronic batch records, AI-enabled deviation monitoring, and validated data platforms should be integrated under GMP-compliant governance. For viral vector and genome-editing programs, leaders should focus on yield improvement, scalable purification, full-empty capsid analytics, off-target assessment support, and lifecycle process validation. Workforce development is equally critical; cross-functional teams need expertise in aseptic processing, cell biology, vector engineering, quality assurance, regulatory affairs, automation, and cold-chain operations. Finally, global manufacturing networks should balance centralized expertise with regional redundancy to support clinical trial continuity, commercial readiness, and timely delivery of patient-specific therapies.Research Methodology
This executive summary is developed using a structured secondary research approach focused on verified, data-backed industry evidence from regulatory agencies, clinical trial registries, peer-reviewed scientific publications, public health authorities, standards organizations, industry guidance documents, and publicly available policy resources. The methodology emphasizes qualitative synthesis rather than market estimation, sizing, share analysis, or forecasting. Research inputs include guidance on advanced therapy medicinal products, biologics manufacturing, GMP compliance, CMC expectations, pharmacovigilance, long-term follow-up, sterility assurance, viral vector characterization, and cell therapy processing. Regional and country insights are assessed through indicators such as regulatory maturity, clinical trial activity, research infrastructure, biomanufacturing capability, healthcare system readiness, workforce development, cold-chain capacity, and public policy support for biotechnology and regenerative medicine. Technology analysis reviews manufacturing platforms, automation, single-use systems, digital quality tools, AI applications, analytical testing, cryopreservation, and supply-chain controls. The findings are triangulated across multiple credible sources to identify consistent themes, operational constraints, and strategic implications. No proprietary company claims, unverified promotional statements, or speculative financial projections are used. The result is an evidence-oriented perspective on how cell and gene therapy manufacturing services are evolving across therapies, regions, technology platforms, and regulatory environments.Conclusion
Cell and gene therapy manufacturing services are becoming a decisive capability in the global transition toward personalized, curative, and genetically targeted medicine. The sector’s progress depends on solving complex challenges in process scalability, viral vector production, analytical validation, contamination control, chain-of-identity management, and regulatory documentation. Regional ecosystems are developing at different levels of maturity, with North America and Europe providing established regulatory and manufacturing depth, Asia-Pacific expanding rapidly through biotechnology investment and clinical activity, and emerging regions building foundational capabilities through healthcare modernization and research collaboration. Artificial intelligence, automation, closed processing, and advanced analytics are reshaping operational models, but their value depends on validated implementation, skilled personnel, and robust quality systems. Industry leaders that combine early CMC discipline, resilient supply chains, scalable platforms, strong analytical science, and regional manufacturing strategies will be better positioned to support safe, consistent, and timely delivery of advanced therapies. As clinical pipelines continue to diversify across oncology, rare diseases, immune disorders, and inherited conditions, manufacturing services will remain a critical determinant of whether scientific breakthroughs can reliably reach patients.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
7. Cell & Gene Therapy Manufacturing Services Market, by Service Type
8. Cell & Gene Therapy Manufacturing Services Market, by Manufacturing Process
9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type
10. Cell & Gene Therapy Manufacturing Services Market, by Cell Type
11. Cell & Gene Therapy Manufacturing Services Market, by Delivery Mode
12. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area
13. Cell & Gene Therapy Manufacturing Services Market, by Application
14. Cell & Gene Therapy Manufacturing Services Market, by End-User
15. Cell & Gene Therapy Manufacturing Services Market, by Region
16. Cell & Gene Therapy Manufacturing Services Market, by Group
17. Cell & Gene Therapy Manufacturing Services Market, by Country
18. Competitive Landscape
19. Company Profiles
List of Figures
List of Tables
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Charles River Laboratories International, Inc.
- C.H. Boehringer Sohn AG & Co. KG
- Merck KGaA
- Fujifilm Holdings Corporation
- Novartis AG
- Takara Bio Inc.
- Danaher Corporation
- WuXi AppTec Co., Ltd.
- Bio-Techne Corporation
- Catalent, Inc. by Novo Holdings A/S
- Recipharm AB
- AGC Biologics
- Advanced BioScience Laboratories, Inc. by Institut Mérieux
- Cell Therapies Pty Ltd.
- Cell-Easy
- eXmoor Pharma Concepts Limited
- Genezen Laboratories, Inc.
- Laboratory Corporation of America Holdings
- Miltenyi Biotec B.V. & Co. KG
- Minaris Regenerative Medicine GmbH
- Nikon Corporation
- Oxford Biomedica PLC
- ProPharma Group Holdings, LLC
- Samsung Biologics Co., Ltd.
- SGS S.A.
- STEMCELL Technologies Inc.
- uBriGene Biosciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | July 2026 |
| Forecast Period | 2026 - 2032 |
| Estimated Market Value ( USD | $ 19.75 Billion |
| Forecasted Market Value ( USD | $ 49.42 Billion |
| Compound Annual Growth Rate | 16.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
